Can Nice Guy Teva Mate With Nasty Mylan?

The U.S. company’s response to the Israeli drug maker’s takeover bid was unusually harsh, but analyst says odds are Teva can prevail.

comments Print
Even by the rough-and-tumble standards of hard-fought merger and acquisition deals, Mylan’s reaction to Teva Pharmaceuticals’ unsolicited bid to acquire the U.S. drug maker was unusually harsh. Teva’s...